Cell-Penetrating Pepducin Therapy Targeting PAR1 in Supjects with Coronary Artery Disease

Paul A. Gurbel, Kevin P. Bliden, Susan E. Turner, Udaya S. Tantry, Martin G. Gesheff, Travis P. Barr, Lidija Covic, Athan Kuliopulos

Research output: Contribution to journalArticle

Abstract

Objective-Pepducins are membrane-tethered, cell-penetrating lipopeptides that target the cytoplasmic surface of their cognate receptor. Here, we report the first human use of a protease-activated receptor-1-based pepducin, which is intended as an antiplatelet agent to prevent ischemic complications of percutaneous coronary interventions. Approach and Results-PZ-128 was administered by 1 to 2 hours continuous intravenous infusion (0.01-2 mg/kg) to 31 supjects with coronary artery disease or multiple coronary artery disease risk factors. Safety, antiplatelet efficacy, and pharmacokinetics were assessed at baseline and 0.5, 1, 2, 6, 24 hours, and 7 to 10 days postdosing. The inhibitory effects of PZ-128 on platelet aggregation stimulated by the protease-activated receptor-1 agonist SFLLRN (8 μmol/L) at 30 minutes to 6 hours were dose dependent with 20% to 40% inhibition at 0.3 mg/kg, 40% to 60% at 0.5 mg/kg, and ≥80% to 100% at 1 to 2 mg/kg. The supgroup receiving aspirin in the 0.5 and 1-mg/kg dose cohorts had 65% to 100% inhibition of final aggregation to SFLLRN at 30 minutes to 2 hours and 95% to 100% inhibition by 6 hours. The inhibitory effects of 0.5 mg/kg PZ-128 were reversible with 50% recovery of aggregation to SFLLRN by 24 hours. There were no significant effects of PZ-128 on aggregation induced by AYPGKF, ADP, or collagen, indicating that the observed effects were specific to protease-activated receptor-1. The plasma half-life was 1.3 to 1.8 hours, and PZ-128 was nondetectable in urine. There were no effects on bleeding, coagulation, clinical chemistry, or ECG parameters. Conclusions-PZ-128 is a promising antiplatelet agent that provides rapid, specific, dose dependent, and reversible inhibition of platelet protease-activated receptor-1 through a novel intracellular mechanism. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01806077.

Original languageEnglish (US)
Pages (from-to)189-197
Number of pages9
JournalArteriosclerosis, Thrombosis, and Vascular Biology
Volume36
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

PAR-1 Receptor
Coronary Artery Disease
Platelet Aggregation Inhibitors
Lipopeptides
Clinical Chemistry
Percutaneous Coronary Intervention
Therapeutics
Platelet Aggregation
Intravenous Infusions
Adenosine Diphosphate
Aspirin
Half-Life
Electrocardiography
Collagen
Blood Platelets
Pharmacokinetics
Cell Membrane
Clinical Trials
Urine
Hemorrhage

Keywords

  • aspirin
  • collagen
  • coronary artery disease
  • lipopeptides
  • risk factors

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Gurbel, P. A., Bliden, K. P., Turner, S. E., Tantry, U. S., Gesheff, M. G., Barr, T. P., ... Kuliopulos, A. (2016). Cell-Penetrating Pepducin Therapy Targeting PAR1 in Supjects with Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 36(1), 189-197. https://doi.org/10.1161/ATVBAHA.115.306777

Cell-Penetrating Pepducin Therapy Targeting PAR1 in Supjects with Coronary Artery Disease. / Gurbel, Paul A.; Bliden, Kevin P.; Turner, Susan E.; Tantry, Udaya S.; Gesheff, Martin G.; Barr, Travis P.; Covic, Lidija; Kuliopulos, Athan.

In: Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 36, No. 1, 01.01.2016, p. 189-197.

Research output: Contribution to journalArticle

Gurbel, PA, Bliden, KP, Turner, SE, Tantry, US, Gesheff, MG, Barr, TP, Covic, L & Kuliopulos, A 2016, 'Cell-Penetrating Pepducin Therapy Targeting PAR1 in Supjects with Coronary Artery Disease', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 36, no. 1, pp. 189-197. https://doi.org/10.1161/ATVBAHA.115.306777
Gurbel, Paul A. ; Bliden, Kevin P. ; Turner, Susan E. ; Tantry, Udaya S. ; Gesheff, Martin G. ; Barr, Travis P. ; Covic, Lidija ; Kuliopulos, Athan. / Cell-Penetrating Pepducin Therapy Targeting PAR1 in Supjects with Coronary Artery Disease. In: Arteriosclerosis, Thrombosis, and Vascular Biology. 2016 ; Vol. 36, No. 1. pp. 189-197.
@article{af57a87a9f4d4eda94d5ea2528e8d0c0,
title = "Cell-Penetrating Pepducin Therapy Targeting PAR1 in Supjects with Coronary Artery Disease",
abstract = "Objective-Pepducins are membrane-tethered, cell-penetrating lipopeptides that target the cytoplasmic surface of their cognate receptor. Here, we report the first human use of a protease-activated receptor-1-based pepducin, which is intended as an antiplatelet agent to prevent ischemic complications of percutaneous coronary interventions. Approach and Results-PZ-128 was administered by 1 to 2 hours continuous intravenous infusion (0.01-2 mg/kg) to 31 supjects with coronary artery disease or multiple coronary artery disease risk factors. Safety, antiplatelet efficacy, and pharmacokinetics were assessed at baseline and 0.5, 1, 2, 6, 24 hours, and 7 to 10 days postdosing. The inhibitory effects of PZ-128 on platelet aggregation stimulated by the protease-activated receptor-1 agonist SFLLRN (8 μmol/L) at 30 minutes to 6 hours were dose dependent with 20{\%} to 40{\%} inhibition at 0.3 mg/kg, 40{\%} to 60{\%} at 0.5 mg/kg, and ≥80{\%} to 100{\%} at 1 to 2 mg/kg. The supgroup receiving aspirin in the 0.5 and 1-mg/kg dose cohorts had 65{\%} to 100{\%} inhibition of final aggregation to SFLLRN at 30 minutes to 2 hours and 95{\%} to 100{\%} inhibition by 6 hours. The inhibitory effects of 0.5 mg/kg PZ-128 were reversible with 50{\%} recovery of aggregation to SFLLRN by 24 hours. There were no significant effects of PZ-128 on aggregation induced by AYPGKF, ADP, or collagen, indicating that the observed effects were specific to protease-activated receptor-1. The plasma half-life was 1.3 to 1.8 hours, and PZ-128 was nondetectable in urine. There were no effects on bleeding, coagulation, clinical chemistry, or ECG parameters. Conclusions-PZ-128 is a promising antiplatelet agent that provides rapid, specific, dose dependent, and reversible inhibition of platelet protease-activated receptor-1 through a novel intracellular mechanism. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01806077.",
keywords = "aspirin, collagen, coronary artery disease, lipopeptides, risk factors",
author = "Gurbel, {Paul A.} and Bliden, {Kevin P.} and Turner, {Susan E.} and Tantry, {Udaya S.} and Gesheff, {Martin G.} and Barr, {Travis P.} and Lidija Covic and Athan Kuliopulos",
year = "2016",
month = "1",
day = "1",
doi = "10.1161/ATVBAHA.115.306777",
language = "English (US)",
volume = "36",
pages = "189--197",
journal = "Arteriosclerosis, Thrombosis, and Vascular Biology",
issn = "1079-5642",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Cell-Penetrating Pepducin Therapy Targeting PAR1 in Supjects with Coronary Artery Disease

AU - Gurbel, Paul A.

AU - Bliden, Kevin P.

AU - Turner, Susan E.

AU - Tantry, Udaya S.

AU - Gesheff, Martin G.

AU - Barr, Travis P.

AU - Covic, Lidija

AU - Kuliopulos, Athan

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Objective-Pepducins are membrane-tethered, cell-penetrating lipopeptides that target the cytoplasmic surface of their cognate receptor. Here, we report the first human use of a protease-activated receptor-1-based pepducin, which is intended as an antiplatelet agent to prevent ischemic complications of percutaneous coronary interventions. Approach and Results-PZ-128 was administered by 1 to 2 hours continuous intravenous infusion (0.01-2 mg/kg) to 31 supjects with coronary artery disease or multiple coronary artery disease risk factors. Safety, antiplatelet efficacy, and pharmacokinetics were assessed at baseline and 0.5, 1, 2, 6, 24 hours, and 7 to 10 days postdosing. The inhibitory effects of PZ-128 on platelet aggregation stimulated by the protease-activated receptor-1 agonist SFLLRN (8 μmol/L) at 30 minutes to 6 hours were dose dependent with 20% to 40% inhibition at 0.3 mg/kg, 40% to 60% at 0.5 mg/kg, and ≥80% to 100% at 1 to 2 mg/kg. The supgroup receiving aspirin in the 0.5 and 1-mg/kg dose cohorts had 65% to 100% inhibition of final aggregation to SFLLRN at 30 minutes to 2 hours and 95% to 100% inhibition by 6 hours. The inhibitory effects of 0.5 mg/kg PZ-128 were reversible with 50% recovery of aggregation to SFLLRN by 24 hours. There were no significant effects of PZ-128 on aggregation induced by AYPGKF, ADP, or collagen, indicating that the observed effects were specific to protease-activated receptor-1. The plasma half-life was 1.3 to 1.8 hours, and PZ-128 was nondetectable in urine. There were no effects on bleeding, coagulation, clinical chemistry, or ECG parameters. Conclusions-PZ-128 is a promising antiplatelet agent that provides rapid, specific, dose dependent, and reversible inhibition of platelet protease-activated receptor-1 through a novel intracellular mechanism. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01806077.

AB - Objective-Pepducins are membrane-tethered, cell-penetrating lipopeptides that target the cytoplasmic surface of their cognate receptor. Here, we report the first human use of a protease-activated receptor-1-based pepducin, which is intended as an antiplatelet agent to prevent ischemic complications of percutaneous coronary interventions. Approach and Results-PZ-128 was administered by 1 to 2 hours continuous intravenous infusion (0.01-2 mg/kg) to 31 supjects with coronary artery disease or multiple coronary artery disease risk factors. Safety, antiplatelet efficacy, and pharmacokinetics were assessed at baseline and 0.5, 1, 2, 6, 24 hours, and 7 to 10 days postdosing. The inhibitory effects of PZ-128 on platelet aggregation stimulated by the protease-activated receptor-1 agonist SFLLRN (8 μmol/L) at 30 minutes to 6 hours were dose dependent with 20% to 40% inhibition at 0.3 mg/kg, 40% to 60% at 0.5 mg/kg, and ≥80% to 100% at 1 to 2 mg/kg. The supgroup receiving aspirin in the 0.5 and 1-mg/kg dose cohorts had 65% to 100% inhibition of final aggregation to SFLLRN at 30 minutes to 2 hours and 95% to 100% inhibition by 6 hours. The inhibitory effects of 0.5 mg/kg PZ-128 were reversible with 50% recovery of aggregation to SFLLRN by 24 hours. There were no significant effects of PZ-128 on aggregation induced by AYPGKF, ADP, or collagen, indicating that the observed effects were specific to protease-activated receptor-1. The plasma half-life was 1.3 to 1.8 hours, and PZ-128 was nondetectable in urine. There were no effects on bleeding, coagulation, clinical chemistry, or ECG parameters. Conclusions-PZ-128 is a promising antiplatelet agent that provides rapid, specific, dose dependent, and reversible inhibition of platelet protease-activated receptor-1 through a novel intracellular mechanism. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01806077.

KW - aspirin

KW - collagen

KW - coronary artery disease

KW - lipopeptides

KW - risk factors

UR - http://www.scopus.com/inward/record.url?scp=84952637415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952637415&partnerID=8YFLogxK

U2 - 10.1161/ATVBAHA.115.306777

DO - 10.1161/ATVBAHA.115.306777

M3 - Article

VL - 36

SP - 189

EP - 197

JO - Arteriosclerosis, Thrombosis, and Vascular Biology

JF - Arteriosclerosis, Thrombosis, and Vascular Biology

SN - 1079-5642

IS - 1

ER -